Vevye Solution/ Drops
NDC 82667-900
Product Information
Vevye (cyclosporine ophthalmic solution) is a NDA-approved product labeled by Harrow Eye, Llc. Cyclosporine eye drops are used to treat a certain type of dry eyes. It is supplied as a solution/ drops for ophthalmic administration. This product entry covers the primary NDC 82667-900 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 82667-900?
What are the uses of this product?
What are Active Ingredients of this product?
- CYCLOSPORINE 1 mg/mL - A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CYCLOSPORINE (UNII: 83HN0GTJ6D)
- CYCLOSPORINE (UNII: 83HN0GTJ6D) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- 1,1,1,2,2,3,3,4,4-NONAFLUORONONANE (UNII: M4M23ZL2AD)
- ALCOHOL (UNII: 3K9958V90M)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2639936 - cycloSPORINE 0.1 % Ophthalmic Solution
- RxCUI: 2639936 - cyclosporine 1 MG/ML Ophthalmic Solution
- RxCUI: 2639936 - cyclosporine 0.1 % Ophthalmic Solution
- RxCUI: 2639941 - vevye 0.1 % Ophthalmic Solution
- RxCUI: 2639941 - cyclosporine 1 MG/ML Ophthalmic Solution [Vevye]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.